Loading clinical trials...
Loading clinical trials...
Phase-Ib Study in Male Patients With Stable Allergic Asthma With Airway Hyperresponsiveness to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation - A Randomised, Double-blind, Placebo-controlled, Parallel-group (Per Dose Level) Dose-escalation Study in Asthmatic Patients
Conditions
Interventions
SB010
Placebo
Locations
1
Germany
Clinical Airway Research Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
Hanover, Germany
Start Date
April 1, 2012
Primary Completion Date
August 1, 2012
Completion Date
August 1, 2012
Last Updated
April 29, 2014
NCT07486401
NCT02327897
NCT07219173
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Sterna Biologicals GmbH & Co. KG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions